Trending...
- Street Smart, Future Ready Audible Edition Soars to #1 New Release on Audible!
- MLM Unlimited Enterprise, LLC Announces DBE Certification
- 2025 HFM Symposium - Optimizing the Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports.
TEMECULA, Calif. - JerseyDesk -- Jellyfish Publication-Certified Nutraceuticals, Inc.
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on Jersey Desk
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on Jersey Desk
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on Jersey Desk
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Corner Property Management Appointed Managing Agent for Minneakoning Business Center in Flemington
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on Jersey Desk
- AT Information Products Expands U.S. Access to the Markoprint X1Jet Family of High-Performance Inkjet Printers
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
- Veritext Legal Solutions Participates in Spectrum360's Annual "A Walk for a Lifetime"
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Source: Certified Nutraceuticals, Inc.
Filed Under: Health
0 Comments
Latest on Jersey Desk
- Celebrating Father's Day Weekend with Free Admission for the entire Family, AKC Dog Show, Best in Show and Puppy Event, Product Vendors
- LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
- csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- Corner Property Management Now Managing Van Wagenen Terrace COA in Jersey City, NJ
- Street Smart, Future Ready Audible Edition Soars to #1 New Release on Audible!
- 2025 HFM Symposium - Optimizing the Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure
- MLM Unlimited Enterprise, LLC Announces DBE Certification
- Let's Talk Series: At the Crossroads: Immigration Today
- Cyta Cyprus Selects Axiros' AXESS Platform for Cloud-Native, Data-Driven Device Management
- Protiviti Congratulates Brand Ambassador Jennifer Kupcho on Victory at ShopRite LPGA Classic
- DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
- From Corporate Layoffs to Entrepreneurship: Wingman Offers a New Path Forward
- 2025 HFM Symposium - Managing Hyperkalemia in Heart Failure: Implementing Strategies to Reduce Patient Risk
- Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
- WORLD INSURANCE ASSOCIATES ANNOUNCES BRAND REFRESH, STATES VALUE FOR CLIENTS AND PARTNERS
- VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
- Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
- Cyrus O'Leary's Mini Cream Pies - The Latest Dessert Innovation from Sara Lee Frozen Bakery Delivers Indulgence in Single-Servings